{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:22:24Z","timestamp":1790284944014,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00259-019-04439-9","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T12:03:29Z","timestamp":1565784209000},"page":"881-894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE"],"prefix":"10.1007","volume":"47","author":[{"given":"Josephine","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich-Frank","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Jann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruza","family":"Arsenic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2010-4117","authenticated-orcid":false,"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"issue":"11","key":"4439_CR1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","volume":"340","author":"MH Kulke","year":"1999","unstructured":"Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340(11):858\u201368.","journal-title":"N Engl J Med"},{"issue":"18","key":"4439_CR2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4439_CR3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12022-014-9313-z","volume":"25","author":"G Rindi","year":"2014","unstructured":"Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25(2):186\u201392.","journal-title":"Endocr Pathol"},{"key":"4439_CR4","unstructured":"Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2. JNCCN. 2018;16(6):693\u2013702."},{"issue":"6","key":"4439_CR5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","volume":"35","author":"Z Yang","year":"2011","unstructured":"Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853\u201360.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"4439_CR6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12020-017-1364-8","volume":"57","author":"F Grillo","year":"2017","unstructured":"Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti MP, Cittadini G, et al. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment? Endocrine. 2017;57(3):494\u2013502.","journal-title":"Endocrine."},{"issue":"1","key":"4439_CR7","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1038\/s41598-018-22115-0","volume":"8","author":"D Walter","year":"2018","unstructured":"Walter D, Harter PN, Battke F, Winkelmann R, Schneider M, Holzer K, et al. Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors. Sci Rep. 2018;8(1):3811.","journal-title":"Sci Rep"},{"issue":"4","key":"4439_CR8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.2017-0364","volume":"23","author":"B Nunez-Valdovinos","year":"2018","unstructured":"Nunez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castano-Pascual A, Benavent M, et al. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018;23(4):422\u201332.","journal-title":"Oncologist"},{"key":"4439_CR9","doi-asserted-by":"crossref","unstructured":"Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018.","DOI":"10.1038\/s41588-018-0138-4"},{"key":"4439_CR10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","volume":"733","author":"EP Krenning","year":"1994","unstructured":"Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide: A case history. Ann NY Acad Sci. 1994;733:496\u2013506.","journal-title":"Ann NY Acad Sci"},{"issue":"13","key":"4439_CR11","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4439_CR12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4439_CR13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.01.009","volume":"58","author":"D Horsch","year":"2016","unstructured":"Horsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer (Oxford, England: 1990). 2016;58:41\u201351.","journal-title":"Eur J Cancer"},{"issue":"17","key":"4439_CR14","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416\u201323.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4439_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","volume":"32","author":"R Valkema","year":"2002","unstructured":"Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110\u201322.","journal-title":"Semin Nucl Med"},{"issue":"4","key":"4439_CR16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","volume":"43","author":"ES Delpassand","year":"2014","unstructured":"Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43(4):518\u201325.","journal-title":"Pancreas."},{"issue":"4","key":"4439_CR17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7150\/thno.13702","volume":"6","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics. 2016;6(4):501\u201310.","journal-title":"Theranostics."},{"issue":"4","key":"4439_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000348394","volume":"97","author":"M Sansovini","year":"2013","unstructured":"Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97(4):347\u201354.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"4439_CR19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"4439_CR20","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00259-014-2780-0","volume":"41","author":"V Prasad","year":"2014","unstructured":"Prasad V, Bodei L, Kidd M, Modlin IM. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. Eur J Nucl Med Mol Imaging. 2014;41(10):1825\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"4439_CR21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, Wlodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956\u201375.","journal-title":"Transl Oncol"},{"issue":"1","key":"4439_CR22","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105\u201317.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"4439_CR23","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1038\/emm.2017.165","volume":"50","author":"J Liu","year":"2018","unstructured":"Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50(1):e416.","journal-title":"Exp Mol Med"},{"issue":"2","key":"4439_CR24","first-page":"144","volume":"38","author":"A Saber","year":"2017","unstructured":"Saber A, Hiltermann TJN, Kok K, Terpstra MM, de Lange K, Timens W, et al. Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors. Carcinogenesis. 2017;38(2):144\u201351.","journal-title":"Carcinogenesis."},{"issue":"7","key":"4439_CR25","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017;171(7):1611\u201324.e24.","journal-title":"Cell."},{"key":"4439_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","volume":"64","author":"RE Ellsworth","year":"2017","unstructured":"Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: State of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65\u201372.","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"4439_CR27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcmgh.2014.12.008","volume":"1","author":"M Kidd","year":"2015","unstructured":"Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol. 2015;1(2):131\u201353.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"4439_CR28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00428-017-2093-3","volume":"470","author":"M Charoenpitakchai","year":"2017","unstructured":"Charoenpitakchai M, Liu E, Zhao Z, Koyama T, Huh WJ, Berlin J, et al. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. Virchows Arch. 2017;470(5):545\u201352.","journal-title":"Virchows Arch"},{"issue":"3","key":"4439_CR29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","volume":"21","author":"Rudolf A. Werner","year":"2018","unstructured":"Werner RA, Ilhan H, Lehner S, Papp L, Zsoter N, Schatka I, et al. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol. 2019;21(3):582-590.","journal-title":"Molecular Imaging and Biology"},{"issue":"2","key":"4439_CR30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990). 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4439_CR31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000225951","volume":"90","author":"DJ Kwekkeboom","year":"2009","unstructured":"Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90(2):220\u20136.","journal-title":"Neuroendocrinology."},{"issue":"5","key":"4439_CR32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"4439_CR33","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"4439_CR34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716\u201331.","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"4439_CR35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000477585","volume":"106","author":"S Singh","year":"2018","unstructured":"Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, et al. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018;106(3):211\u201320.","journal-title":"Neuroendocrinology."},{"issue":"3","key":"4439_CR36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","volume":"105","author":"M Pavel","year":"2017","unstructured":"Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017;105(3):266\u201380.","journal-title":"Neuroendocrinology"},{"issue":"9","key":"4439_CR37","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00259-015-3075-9","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Modlin IM, Prasad V, Severi S, Ambrosini V, et al. Gene transcript analysis blood values correlate with (6)(8)Ga-DOTA-somatostatin analog (SSA) PET\/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging. 2015;42(9):1341\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"4439_CR38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-018-3967-6","volume":"45","author":"L Bodei","year":"2018","unstructured":"Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45(7):1155\u201369.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"4439_CR39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","volume":"21","author":"M Jamal-Hanjani","year":"2015","unstructured":"Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258\u201366.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"4439_CR40","first-page":"5969","volume":"50","author":"JC Reubi","year":"1990","unstructured":"Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969\u201377.","journal-title":"Cancer Res"},{"key":"4439_CR41","first-page":"524130","volume":"2011","author":"S Oh","year":"2011","unstructured":"Oh S, Prasad V, Lee DS, Baum RP. Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET\/CT and F-18 FDG PET\/CT. Int J Mol Imaging. 2011;2011:524130.","journal-title":"Int J Mol Imaging"},{"issue":"5","key":"4439_CR42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4439_CR43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11307-016-1018-x","volume":"19","author":"C Wetz","year":"2017","unstructured":"Wetz C, Apostolova I, Steffen IG, Hofheinz F, Furth C, Kupitz D, et al. Predictive Value of Asphericity in Pretherapeutic [(111)In]DTPA-Octreotide SPECT\/CT for Response to Peptide Receptor Radionuclide Therapy with [(177)Lu]DOTATATE. Mol Imaging Biol. 2017;19(3):437\u201345.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"4439_CR44","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.18632\/oncotarget.12402","volume":"8","author":"RA Werner","year":"2017","unstructured":"Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget. 2017;8(4):7039\u201349.","journal-title":"Oncotarget."},{"issue":"8","key":"4439_CR45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","volume":"42","author":"A Sabet","year":"2015","unstructured":"Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42(8):1238\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04439-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04439-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T17:11:29Z","timestamp":1664125889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04439-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4439"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04439-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"28 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Charit\u00e9\u2019s Ethics Committee, which is our institutional review board, approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients consented to the publication of their anonymised data and our institutional review board allowed the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}